

Tillotts Pharma Transfers of Value in 2020 to Swiss Healthcare Professionals and Healthcare Organisations

Date of publication: JUNE 2021

	Full Name (Art. 1.01)	HCPs: City of Principal Practice HCOs: city where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Donations and Grants to HCOs (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL	
						Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	Prof. Dr. Gerhard Rogler MD PH	8032 Zürich	Switzerland	Kapfstrasse 16, CH-8032 Zürich	N/A	N/A			CHF 2'000.00		CHF 2,000.00	
					N/A	N/A					N/A	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A					N/A
	Number of Recipients in aggregate disclosure					N/A	N/A					N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02					N/A	N/A					N/A
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
											N/A	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients						CHF 2692.50					CHF 2,692.50
	Number of Recipients in aggregate disclosure						1					N/A
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02						100%					N/A	
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										N/A	

Methodological Notes

Disclosure by Tillotts Pharma of payments to Swiss healthcare professionals and healthcare organisations in 2020

The Code of conduct of the pharmaceutical industry in Switzerland on cooperation with healthcare professional circles and patient organizations (Pharma Cooperation Code) mandates the public disclosure in 2021 of certain transfers of value made during 2020 to Swiss healthcare professionals and healthcare organisations. The disclosure data will be published on the website of Tillotts Pharma, www.tillotts.com.

The disclosure requirements are set forth in Section 2 of the Pharma Cooperation Code. The methodological notes below explain the data Tillotts Pharma have disclosed and how the data have been prepared, to assist the reader's understanding. Inclusion of these methodological notes alongside the disclosure data is mandated by Articles 281 – 282 of the Pharma Cooperation Code.

VAT

VAT is excluded from all disclosures of transfer of value.

Currency

All disclosures are made in Swiss Francs (CHF). Where the original payment was made in Euros, the sum was converted to Swiss Francs at the 2020 average annual exchange rate published by the European Central Bank (www.ecb.europa.eu).

Consolidated Disclosures of the Corporate Group and Cross-border Payments

The disclosures represent the consolidated transfers of value made by the Tillotts Pharma corporate group in line with the EFPIA Disclosure Code's dictate that separate entities belonging to the same multinational company (which could be the parent company and subsidiary company) shall be deemed to constitute a single company. In 2020, all transfers of value represent payments made by Tillotts Pharma AG.

Multi-year contracts

As a general rule, where multi-year contracts are included in the disclosure of transfer of value made by Tillotts Pharma in 2020, the disclosures related to these multi-year contracts represent the services rendered and paid for in 2020, and/or any expenses incurred and paid for in 2020, in each case under such contracts.

Data Protection

Consent to disclose data

In countries where it is required by applicable data protection laws, Tillotts has taken all reasonable steps to obtain consents from the HCPs, and HCOs, as applicable, to publicly disclose payments and

other transfers of value. In accordance with EFPIA guidance, partial consents are not acceptable. If consent is not provided, the data will be reported on an aggregate level only.

Consent collection and withdrawal

Tillotts respects applicable data protection laws. If a stakeholder withdraws the provided consent, Tillotts will adjust the publication accordingly within a reasonable time.

Data included

The data disclosed by Tillotts Pharma is consistent with the requirements of the Pharma Cooperation Code. The data can be categorised as follows:

Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event

Disclosed data includes payments to healthcare organisations that represent a contribution of costs related to an event. Such data includes the following types of payments paid to the healthcare organisations or to a third party appointed by the healthcare organisation to organize an event: fees for exhibition/booth space at an event; fees for event exhibition badges and event registration fees, in each case for Tillotts Pharma staff and, when applicable, other non-HCP individuals; fees related to advertising at an event; and sponsorship fees related to an event or satellite symposium at an event.

Payment of consultants who provide services to Tillotts Pharma

Disclosed data includes the payment of honoraria to Swiss healthcare professionals in 2020 who provided services to Tillotts Pharma during 2020. Where applicable, the disclosure data also includes payment of reasonable expenses to such consultants incurred in the delivery of their services, such as travel expenses and/or accommodation expenses.